QIAGEN receives FDA Emergency Use Authorization for NeuMoDx multiplex test expanding COVID-19 portfolio
NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test receives Emergency Use Authorization by FDA The 4-plex test utilizes the hi…
NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Test receives Emergency Use Authorization by FDA The 4-plex test utilizes the hi…
• U.S. FDA approves therascreen BRAF V600E RGQ PCR assay as companion diagnostic • Test will help identify patients elig…
. • QIAstat-Dx syndromic testing system can differentiate novel coronavirus from 20 other respiratory targets • Requires…
 First syndromic testing solution to get U.S. agency’s development support in novel coronavirus response QIAstat-Dx R…
• QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify…
. QIAseq® Multimodal Panels vereinfachen die simultane DNA- und RNA-Sequenzierung für ein umfassendes Profiling hämato…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution unde…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its novel therascreen® FGFR R…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a master service agreement with LabCorp® (NYSE:…
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung neuer Lösungen zur Unterstützung der Kr…